KLINIKEN ESSEN SUED Evangelisches Krankenhaus Essen-Werden gGmbH — Clinical Trial Site

13 Registered trials

6 Currently recruiting

Organisation

KLINIKEN ESSEN SUED Evangelisches Krankenhaus Essen-Werden gGmbH

Location

Essen, Germany

Identifier

ORG-100022443

Address

Pattbergstrasse 1-3, Werden, 45239, Germany

Departments

Gynecology & Oncology
Haematologie
Hematology
Klinik für Haematologie, Internistische Onkologie und Stammzelltransplantation
Klinik für Hämatologie, inter. Onkologie und Stammzelltransplantation
Klinik für Hämatologie, Internistische Onkologie und Stammzelltransplantation
Klinik für Hämatologie, Internistische Onkologie & Stammzelltransplantation
Klinik für Hämatologie, Onkologie und Stammzelltransplantation
Zentrum für Innere Medizin - Hämatologie, internistische Onkologie u. Stammzelltransplantation

Clinical trials at this site (13)

Search interface

A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML… Recruiting

2024-512733-32-00 Acute Myeloid Leukemia (AML) 5 2025-03-31
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A Study of Duvelisib Versus the Anti-cancer Drugs Gemcitabine or Bendamustine in Patients With T Cell lymphoma (a type of blood cancer), whi… Recruiting

2024-516605-23-00 relapsed/refractory nodal T cell lymphoma with T follic 5 2025-05-12
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i… Recruiting

2023-508204-38-00 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) 5 2024-07-02
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate pol… Ended

2024-513949-37-00 previously untreated aggressive B-cell lymphoma 4 2023-03-16
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15